Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zetomipzomib maleate (KZR-616), a novel immunoproteasome inhibitor, effectively and selectively inhibits the LMP7 subunit (hLMP7/mLMP7 IC50: 39/57 nM) and LMP2 subunit (hLMP7/mLMP7 IC50: 131/179 nM) of the immunoproteasome. This compound shows promising potential for research in various autoimmune diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $1,490 | Backorder |
Description | Zetomipzomib maleate (KZR-616), a novel immunoproteasome inhibitor, effectively and selectively inhibits the LMP7 subunit (hLMP7/mLMP7 IC50: 39/57 nM) and LMP2 subunit (hLMP7/mLMP7 IC50: 131/179 nM) of the immunoproteasome. This compound shows promising potential for research in various autoimmune diseases. |
In vitro | Zetomipzomib maleate also inhibits MECL-1 subunit (IC 50 =623 nM) and constitutive proteasome β5 subunit (IC 50 =688 nM). Zetomipzomib maleate maintains LMP7 and LMP2 selective inhibition in MOLT-4 cells. Zetomipzomib maleate (250 nM) shows a comparable cytokine inhibition profile peripheral blood mononuclear cells (PBMC)[1]. Zetomipzomib maleate is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914 and PR-924[3]. |
In vivo | Zetomipzomib maleate, administered intravenously (i.v.) at a dosage of 5 mg/kg, demonstrated effectiveness in the anticollagen antibody induced arthritis (CAIA) model[1]. This study utilized 7-8 week old female BALB/c mice, with dosing repeated on days 6, 8, 11, and 13. The results highlighted zetomipzomib maleate's potential in mitigating CAIA, marking it as efficacious in this specific animal model. |
Alias | Zetomipzomib maleate, KZR-616 maleate |
Molecular Weight | 702.758 |
Formula | C34H46N4O12 |
Cas No. | 2170983-62-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.